Revvity reported $2.91B of revenue over the trailing twelve months, +4.1% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $2.91B (to Q2 2026). Net income: $238M, trailing twelve months to Q2 2026. Free cash flow: $558M, trailing twelve months to Q2 2026. Operating margin: 12%, trailing twelve months to Q2 2026.

RVTYRevvity

Healthcare

$154.08+76% 1Y

$154.08

$82.2652 weeks$157.37

RVTY as reported

Revvity reported $2.91B of revenue over the trailing twelve months, +4.1% on the year before. 11 reported series are charted on this page, each one as filed.

$2.91B

Revenue, trailing twelve months · to Q2 2026 · +4.1% against the twelve months before

Net income: $238M
Net income · −17% year on year · trailing twelve months to Q2 2026
Free cash flow: $558M
Free cash flow · +11% year on year · trailing twelve months to Q2 2026
Operating margin: 12%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for RVTY, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$2.91B	+4.1%	Q2 2026
Net income	$238M	−17%	Q2 2026
EPS	$2.09	−11%	Q2 2026
Gross margin	57%	n/a	Q3 2023 · 11 quarters behind
Operating margin	12%	n/a	Q2 2026
Net margin	8.1%	n/a	Q2 2026
ROE	3.3%	n/a	Q2 2026
ROA	2.0%	n/a	Q2 2026
ROIC	3.0%	n/a	Q2 2026
Free cash flow	$558M	+11%	Q2 2026
P/E	73.7	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.